Human immunodeficiency virus type 1 infection in oman

Antiretroviral therapy and frequencies of drug resistance mutations

Said H.S. Al Dhahry, Euan M. Scrimgeour, Abdul Raouf Al Suwaid, Mohammed R.M.Y. Al Lawati, Hussein S. El Khatim, Muhannad F. Al Kobaisi, Thomas C. Merigan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Highly active antiretroviral therapy (HAART), consisting mainly of two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI), is offered to <10% of HIV-infected subjects in Oman. The aims of the present study were to determine the frequency of resistance-associated mutations in these patients, and to assess the contribution of drug resistance to treatment outcome. Among 29 patients on HAART for ≥6 months, virological, failure was observed in 27 (93%). Genotypic analysis indicated that in five of these 27 patients, there were no mutations that confer resistance to reverse transcriptase inhibitors (RTIs). The genotypes of 17 other patients carried one or two RTI mutations, mainly the lamivudine-associated resistance mutation M184V. Three or more RTI mutations were found in only five (14.7%) patients with virological failure, including three patients on the nonnucleoside RTI efavirenz. Major PI mutations were infrequent, and were detected in seven (26%) of 27 patients failing HAART, mainly as single mutation at codons 82 or 90. In contrast, accessory mutations in the protease gene were present in all patients. However, there were significant differences in the prevalence of accessory mutations at codons 36 and 77 among clade B and non-B viruses. When genotypic data of this study were used to change therapy of seven patients whose isolates had multiple resistance mutations, adequate viral suppression was observed in five. Our results indicate that the high rate of treatment failure among patients in Oman is mainly due to factors other than resistance to antiretroviral drugs. These factors, which may include nonadherence to therapy and treatment interruptions, need to be investigated.

Original languageEnglish
Pages (from-to)1166-1172
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume20
Issue number11
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Oman
Virus Diseases
Drug Resistance
HIV-1
Mutation
Reverse Transcriptase Inhibitors
Highly Active Antiretroviral Therapy
Therapeutics
efavirenz
Protease Inhibitors
Codon
Lamivudine
R Factors
Treatment Failure
Nucleosides
Peptide Hydrolases
Genotype
HIV

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Al Dhahry, S. H. S., Scrimgeour, E. M., Al Suwaid, A. R., Al Lawati, M. R. M. Y., El Khatim, H. S., Al Kobaisi, M. F., & Merigan, T. C. (2004). Human immunodeficiency virus type 1 infection in oman: Antiretroviral therapy and frequencies of drug resistance mutations. AIDS Research and Human Retroviruses, 20(11), 1166-1172. https://doi.org/10.1089/aid.2004.20.1166

Human immunodeficiency virus type 1 infection in oman : Antiretroviral therapy and frequencies of drug resistance mutations. / Al Dhahry, Said H.S.; Scrimgeour, Euan M.; Al Suwaid, Abdul Raouf; Al Lawati, Mohammed R.M.Y.; El Khatim, Hussein S.; Al Kobaisi, Muhannad F.; Merigan, Thomas C.

In: AIDS Research and Human Retroviruses, Vol. 20, No. 11, 11.2004, p. 1166-1172.

Research output: Contribution to journalArticle

Al Dhahry, Said H.S. ; Scrimgeour, Euan M. ; Al Suwaid, Abdul Raouf ; Al Lawati, Mohammed R.M.Y. ; El Khatim, Hussein S. ; Al Kobaisi, Muhannad F. ; Merigan, Thomas C. / Human immunodeficiency virus type 1 infection in oman : Antiretroviral therapy and frequencies of drug resistance mutations. In: AIDS Research and Human Retroviruses. 2004 ; Vol. 20, No. 11. pp. 1166-1172.
@article{92b1d9cb2a2c4f7ba9038760f89360b0,
title = "Human immunodeficiency virus type 1 infection in oman: Antiretroviral therapy and frequencies of drug resistance mutations",
abstract = "Highly active antiretroviral therapy (HAART), consisting mainly of two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI), is offered to <10{\%} of HIV-infected subjects in Oman. The aims of the present study were to determine the frequency of resistance-associated mutations in these patients, and to assess the contribution of drug resistance to treatment outcome. Among 29 patients on HAART for ≥6 months, virological, failure was observed in 27 (93{\%}). Genotypic analysis indicated that in five of these 27 patients, there were no mutations that confer resistance to reverse transcriptase inhibitors (RTIs). The genotypes of 17 other patients carried one or two RTI mutations, mainly the lamivudine-associated resistance mutation M184V. Three or more RTI mutations were found in only five (14.7{\%}) patients with virological failure, including three patients on the nonnucleoside RTI efavirenz. Major PI mutations were infrequent, and were detected in seven (26{\%}) of 27 patients failing HAART, mainly as single mutation at codons 82 or 90. In contrast, accessory mutations in the protease gene were present in all patients. However, there were significant differences in the prevalence of accessory mutations at codons 36 and 77 among clade B and non-B viruses. When genotypic data of this study were used to change therapy of seven patients whose isolates had multiple resistance mutations, adequate viral suppression was observed in five. Our results indicate that the high rate of treatment failure among patients in Oman is mainly due to factors other than resistance to antiretroviral drugs. These factors, which may include nonadherence to therapy and treatment interruptions, need to be investigated.",
author = "{Al Dhahry}, {Said H.S.} and Scrimgeour, {Euan M.} and {Al Suwaid}, {Abdul Raouf} and {Al Lawati}, {Mohammed R.M.Y.} and {El Khatim}, {Hussein S.} and {Al Kobaisi}, {Muhannad F.} and Merigan, {Thomas C.}",
year = "2004",
month = "11",
doi = "10.1089/aid.2004.20.1166",
language = "English",
volume = "20",
pages = "1166--1172",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Human immunodeficiency virus type 1 infection in oman

T2 - Antiretroviral therapy and frequencies of drug resistance mutations

AU - Al Dhahry, Said H.S.

AU - Scrimgeour, Euan M.

AU - Al Suwaid, Abdul Raouf

AU - Al Lawati, Mohammed R.M.Y.

AU - El Khatim, Hussein S.

AU - Al Kobaisi, Muhannad F.

AU - Merigan, Thomas C.

PY - 2004/11

Y1 - 2004/11

N2 - Highly active antiretroviral therapy (HAART), consisting mainly of two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI), is offered to <10% of HIV-infected subjects in Oman. The aims of the present study were to determine the frequency of resistance-associated mutations in these patients, and to assess the contribution of drug resistance to treatment outcome. Among 29 patients on HAART for ≥6 months, virological, failure was observed in 27 (93%). Genotypic analysis indicated that in five of these 27 patients, there were no mutations that confer resistance to reverse transcriptase inhibitors (RTIs). The genotypes of 17 other patients carried one or two RTI mutations, mainly the lamivudine-associated resistance mutation M184V. Three or more RTI mutations were found in only five (14.7%) patients with virological failure, including three patients on the nonnucleoside RTI efavirenz. Major PI mutations were infrequent, and were detected in seven (26%) of 27 patients failing HAART, mainly as single mutation at codons 82 or 90. In contrast, accessory mutations in the protease gene were present in all patients. However, there were significant differences in the prevalence of accessory mutations at codons 36 and 77 among clade B and non-B viruses. When genotypic data of this study were used to change therapy of seven patients whose isolates had multiple resistance mutations, adequate viral suppression was observed in five. Our results indicate that the high rate of treatment failure among patients in Oman is mainly due to factors other than resistance to antiretroviral drugs. These factors, which may include nonadherence to therapy and treatment interruptions, need to be investigated.

AB - Highly active antiretroviral therapy (HAART), consisting mainly of two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI), is offered to <10% of HIV-infected subjects in Oman. The aims of the present study were to determine the frequency of resistance-associated mutations in these patients, and to assess the contribution of drug resistance to treatment outcome. Among 29 patients on HAART for ≥6 months, virological, failure was observed in 27 (93%). Genotypic analysis indicated that in five of these 27 patients, there were no mutations that confer resistance to reverse transcriptase inhibitors (RTIs). The genotypes of 17 other patients carried one or two RTI mutations, mainly the lamivudine-associated resistance mutation M184V. Three or more RTI mutations were found in only five (14.7%) patients with virological failure, including three patients on the nonnucleoside RTI efavirenz. Major PI mutations were infrequent, and were detected in seven (26%) of 27 patients failing HAART, mainly as single mutation at codons 82 or 90. In contrast, accessory mutations in the protease gene were present in all patients. However, there were significant differences in the prevalence of accessory mutations at codons 36 and 77 among clade B and non-B viruses. When genotypic data of this study were used to change therapy of seven patients whose isolates had multiple resistance mutations, adequate viral suppression was observed in five. Our results indicate that the high rate of treatment failure among patients in Oman is mainly due to factors other than resistance to antiretroviral drugs. These factors, which may include nonadherence to therapy and treatment interruptions, need to be investigated.

UR - http://www.scopus.com/inward/record.url?scp=9344255455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344255455&partnerID=8YFLogxK

U2 - 10.1089/aid.2004.20.1166

DO - 10.1089/aid.2004.20.1166

M3 - Article

VL - 20

SP - 1166

EP - 1172

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -